The role of metabolic reprogramming in liver cancer and its clinical perspectives
Primary liver cancer (PLC), which includes hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA), remains a leading cause of cancer-related death worldwide. Chronic liver diseases, such as hepatitis B and C infections and metabolic dysfunction-associated steatotic liver disease (...
Saved in:
| Main Authors: | Mengxiao Lu, Yingjie Wu, MinMing Xia, Yixin Zhang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-11-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1454161/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Natural History of Metabolic Dysfunction-Associated Steatotic Liver Disease: From Metabolic Syndrome to Hepatocellular Carcinoma
by: Melchor Alpízar Salazar, et al.
Published: (2025-01-01) -
Steatotic Liver Disease: New Nomenclature and Its Localization in the Russian Federation
by: K. L. Raikhelson, et al.
Published: (2024-05-01) -
Metabolic associated steatotic liver disease misses fewer high-risk patients than metabolic associated fatty liver disease
by: Yu-Ming Cheng, et al.
Published: (2024-12-01) -
Low-dose valine attenuates diet-induced metabolic dysfunction-associated steatotic liver disease (MASLD) in mice by enhancing leptin sensitivity and modulating the gut microbiome
by: Felicianna, et al.
Published: (2024-12-01) -
Evaluating the Role of Aspirin in Liver Disease: Efficacy, Safety, Potential Benefits and Risks
by: Amani Elshaer, et al.
Published: (2024-12-01)